Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine zipper tumor suppressor 1 (LZTS1)
- Target
- LZTS1
- Molecular classification
- Tumor suppressor protein, Transcription factor (leucine zipper-containing protein), Cell cycle regulator, Epigenetic regulator (potential)
01
Overview
Leucine zipper tumor suppressor 1 (LZTS1) is a ubiquitously expressed tumor suppressor protein containing a leucine zipper motif, often deleted or downregulated in various malignancies. LZTS1 regulates cell-cycle progression by interacting with key mitotic regulators such as Cdk1/cyclinB1 and CDC25C phosphatase. Its loss or inactivation leads to uncontrolled cell proliferation, impaired mitotic control, and heightened metastatic potential in tumors. LZTS1 also influences epithelial cell differentiation and E-cadherin-mediated adhesion; its downregulation is linked to promotion of epithelial-mesenchymal transition (EMT) and poor prognosis, especially in gastric and colorectal cancers. LZTS1 is considered a prognostic biomarker but is not currently a direct molecular drug target.
- Other names
- LZTS1FEZ1F37
02
Mechanism of action
Inhibition of cell proliferation via interaction with Cdk1/cyclinB1 complex and CDC25C phosphatase. Suppression of mitosis, leading to decreased tumor growth. Stabilization of E-cadherin-mediated adherens junctions, impacting cell adhesion and differentiation. Negative regulation of the PI3K-AKT pathway in some contexts.
03
Biological functions
Regulation of cell cycleCell proliferationApoptosisMitosis control (interaction with the Cdk1/cyclinB1 complex and CDC25C phosphatase)Regulation of microtubule assembly and neuronal migrationPromotion of epithelial cell differentiationRegulation of epithelial-mesenchymal transition (EMT)
04
Disease associations
Cancer (downregulation/mutation associated with various cancers: uveal melanoma, colorectal, breast, lung, esophageal, prostate)Metastasis inhibition (loss of LZTS1 promotes metastatic potential)Cell cycle dysregulation is linked to tumorigenesis
05
Safety considerations
Targeting a tumor suppressor gene/protein directly is clinically challenging; risks include off-target effects and disruption of cell cycle regulation in normal tissuesNo specific therapeutic agents targeting LZTS1 are approved, so practical safety concerns in clinical pharmacology are limited to general tumor suppressor targeting
06
Biomarkers
LZTS1 expression levels (downregulation as prognostic marker in various cancers, especially gastric cancer)LZTS1 promoter methylation status (hypomethylation associated with increased expression in colorectal cancer)E-cadherin (correlated marker in EMT and cell adhesion contexts)
Beyond the preview
Go deeper on Leucine zipper tumor suppressor 1 (LZTS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine zipper tumor suppressor 1 (LZTS1).